Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer

Chiara Romano 1,2,†, Federica Martorana 1,2,‡, Maria Stella Pennisi 1,2, Stefania Stella 1,2, Michele Massimino 1,2, Elena Tirrò 1,3,‡, Silvia Rita Vitale 1,2, Sandra Di Gregorio 1,2, Adriana Puma 1,2, Cristina Tomarchio 1,2 and Livia Manzella 1,2,*

1 Center of Experimental Oncology and Hematology, A.O.U. Policlinico—G. Rodolico—San Marco, 95123 Catania, Italy; federica.martorana@phd.unict.it (F.M.); pery76@gmail.com (M.S.P.); stefania.stel@gmail.com (S.S.); micheledot@yahoo.it (M.M.); elena.tirro@unipa.it (E.T.); silviarita.vitale@gmail.com (S.R.V.); digregoriosandra@hotmail.com (S.D.G.); adry.p88@hotmail.it (A.P.); cristina.tomarchio@hotmail.it (C.T.)

2 Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy

3 Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, 90127 Palermo, Italy

* Correspondence: manzella@unict.it; Tel.: +39-095-3781970
† C.R. and F.M. equally contributed to this work.

Abstract: Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid cancers display some controversial aspects that represent unmet medical needs. Liquid biopsy is a non-invasive approach that detects and analyzes biological samples released from the tumor into the bloodstream. With the use of different technologies, tumor cells, free nucleic acids, and extracellular vesicles can be retrieved in the serum of cancer patients and valuable molecular information can be obtained. Recently, a growing body of evidence is accumulating concerning the use of liquid biopsy in thyroid cancer, as it can be exploited to define a patient’s diagnosis, estimate their prognosis, and monitor tumor recurrence or treatment response. Indeed, liquid biopsy can be a valuable tool to overcome the limits of conventional management of thyroid malignancies. In this review, we summarize currently available data about liquid biopsy in differentiated, poorly differentiated/anaplastic, and medullary thyroid cancer, focusing on circulating tumor cells, circulating free nucleic acids, and extracellular vesicles.

Keywords: differentiated thyroid cancer; anaplastic thyroid cancer; medullary thyroid cancer; liquid biopsy; diagnosis; prognosis; therapy

1. Introduction

Thyroid cancer (TC) is the most frequent endocrine malignancy, accounting for about 2% of total cancers [1,2]. Worldwide, its incidence has increased three-fold over the past 30 years because of screening intensification and environmental and lifestyle changes [3]. The vast majority of TCs have an epithelial origin and include differentiated (DTC), poorly differentiated (PDTC), and anaplastic (ATC) tumors [1,4]. Differentiated TCs, which usually display an indolent clinical behavior and a favorable prognosis, can be further classified as papillary (PTC) (85–90%), follicular (FTC) (5–10%), and Hurthle cell (HCTC) (3%) carcinomas [5,6]. Poorly differentiated and anaplastic TCs are rarer, but they are characterized by an aggressive course and a poor prognosis [7]. Finally, a small proportion of TCs stem from neuroendocrine C-cells and present medullary histotypes (B-Raf proto-oncogene MTCs): up to one quarter (25%) of these tumors are familiar [8].

The biological features of TCs have been extensively investigated. Among DTCs, molecular alterations frequently involve B-Raf proto-oncogene (BRAF) and Rat Sarcoma (RAS) oncogene or gene fusions involving Ret proto-oncogene (RET), while deregulation of
TP53 and Wingless/Integrated (Wnt)/β-catenin pathways are mainly implicated in their progression and dedifferentiation [9–12]. In 98% of inherited and up to 45% of sporadic MTCs, single nucleotide substitutions of RET are present [13]. Recently, micro-RNAs (mi-RNAs) also appear to play a role in TC biology [14], and different mi-RNAs signatures correlate with the malignant potential of thyroid nodules as well as with TCs subtypes and their aggressiveness [15,16].

Despite this deep biological knowledge, clinical management of TCs still presents controversies. Although fine needle aspiration biopsy (FNAB) represents the current gold standard for initial diagnosis of TC, it exhibits some limitations due to the high incidence of non-diagnostic results, especially in the case of follicular lesions [17] (Figure 1). In the post-surgical follow-up of DTC, monitoring thyroglobulin (Tg) levels is a routine practice. However, the presence of anti-Tg-antibodies (TgAb) may interfere with Tg measurement, thus hampering its potential utility as a tumor marker [18]. Additionally, while the majority of DTCs can be cured with surgery followed by hormone replacement and radioactive iodine (RAI, also called I-131) [6], the management of advanced, poorly differentiated, and anaplastic TCs is far more challenging [19–21]. These tumors can be treated with tyrosine kinase inhibitors (TKIs) [22], such as lenvatinib and sorafenib for DTC, dabrafenib, trametinib, and vemurafenib for BRAF mutated PTC or ATC, cabozantinib and vandetanib for MTC, or selpercatinib in RET mutated MTCs [10,23,24].

Figure 1. Advantages of liquid biopsy over tissue biopsy in thyroid cancer. FNAB, fine needle aspiration biopsy.

In this scenario, liquid biopsy can be a valuable resource to assist TC management, as it can be exploited to define the correct diagnosis, predict tumor prognosis, monitor disease evolution, and establish pharmacological approaches [25] (Figure 1). Using liquid biopsy, circulating tumor cells (CTCs), circulating free nucleic acids (cf-DNA, cf-RNA and mi-RNA), and tumor-derived extracellular vesicles (EVs) released in the bloodstream can
be detected and analyzed [26]. Further, CTCs are shed from the tumor mass and enter circulation, where they can remain unitary, cluster together, or lodge in new tissues to form metastasis [27]. Circulating free-DNA released from cancer cells in 160–180 base pairs fragments (i.e., circulating tumor-DNA (ct-DNA)) can contain information about molecular alterations present in the primary tumor [27–30]. Circulating free-DNA and circulating mi-RNAs are most stable, thus easier to investigate, compared to cf-RNA [31]. Extracellular vesicles are micro-particles released in the bloodstream from tumor and normal cells containing proteins, DNA, RNA, mi-RNA, lipids, and metabolites [32,33].

In this review, we provide an overview of liquid biopsy applications in different TC histotypes, focusing on its use in the diagnosis, prognostic definition, and treatment of these diseases.

2. Liquid Biopsy in Differentiated Thyroid Cancer

2.1. Liquid Biopsy in the Diagnosis of Differentiated Thyroid Cancer

Circulating tumor cells, cf-DNA, cf-RNA, mi-RNAs, and EVs may represent a source of information in the diagnostic workup of primary or recurrent DTCs (Figure 2a and Table 1).

Figure 2. Potential implications of liquid biopsy for the diagnosis, prognostic definition, and therapy of differentiated (a), poorly differentiated/anaplastic (b), and medullary (c) thyroid cancer. cf-DNA, circulating free-DNA; cf-RNA, circulating free-RNA; CTC, circulating tumor cells; DTC, differentiated thyroid cancer; EV, extracellular vesicles; mi-RNA, micro-RNA; MTC, medullary thyroid cancer; PDTC/ATC, poorly differentiated thyroid cancer/anaplastic thyroid cancer.
Table 1. Potential implications of liquid biopsy for the diagnosis, prognostic definition, and therapy of differentiated thyroid cancer.

| Clinical Application | Sample Type | Object | Modification | References |
|----------------------|-------------|--------|--------------|------------|
| Diagnosis            | CTC         | Expression of the CTC-associated gene *SLC5A5* | Lower in FTC than FA | [34]       |
|                      |             | Expression of the CTC-associated gene *LGALS3* | Higher in PTC than FTC | [34]       |
|                      |             | Serum level of CEC | Higher in recurrent PTC | [35]       |
|                      | cf-DNA      | cf-DNA quantity and integrity | Higher in DTC | [36,37]     |
|                      |             | cf-DNA quantity and integrity | More common in PTC than FTC | [38]       |
|                      |             | Metilation level of 5 genes on cf-DNA | Higher in DTC than benign nodules | [39]       |
|                      |             | Hypermethylation of MGMT promoter in ct-DNA | Decreased in TC | [40]       |
|                      |             | cf-DNA quantity, *BRAF-V600E* detection, *SLCA8* and *SLC26A4* hypermethylation | Coexist in PTC | [42]       |
|                      | cf-RNA      | Serum level of CEA mRNA | Found in FTC but not in FA | [43]       |
|                      |             | Serum level of TSHR mRNA | Higher in DTC | [44]       |
|                      | mi-RNA      | mi-RNA-375, 34a, 145b, 221, 222, 155, Let-7, 181b, mi-RNA-222 | Higher in PTC than benign nodules | [45]       |
|                      |             | let-7a, let-7c, let-7d, let-7f, mi-RNA-146 and mi-RNA-221 | Higher in PTC | [46]       |
|                      |             | | Higher in FTC than FA | [47]       |
|                      | EV          | mi-RNA-31–5p, mi-RNA-21 and mi-RNA-181a-5p, Let-7b, Let-7d, Let-7f and Let-7g | Higher in PTC | [48]       |
|                      |             | Differentiated FTC from PTC | [49]       |
|                      |             | Higher in FTC than FA | [50]       |
| Prognosis            | CTC         | CTC count | Higher in metastatic DTC or poor responder to RAI | [51]       |
|                      |             | CTC number | Higher in advanced DTC stage | [52]       |
|                      | cf-DNA      | *BRAF-V600E* detection | Associated with disease aggressiveness in PTC | [53]       |
|                      | mi-RNA      | mi-RNA-222 and mi-RNA-146 | Higher in DTC with poor outcome | [54]       |
| Therapy              | CTC         | CEC count | Decreased in DTC responding to RAI therapy | [55]       |
|                      |             | CTCs expressing NIS | Decreased in DTC responding to RAI therapy | [56]       |
|                      | cf-DNA      | ct-DNA levels, *BRAF-V600E* detection, ct-DNA copy number | Higher in poor responder or unresponsive DTC | [57]       |
|                      |             | *BRAF-V600E* detection | Associated to incomplete response to RAI in PTC | [53]       |
|                      |             | ct-DNA copy number | Higher in PTC with minimal residual disease | [58]       |
|                      |             | | Higher in PTC with residual disease after surgery | [59]       |
|                      | cf-RNA      | Level of *BRAF-V600E* cf-RNA | Decrease in FTC during RAI or TKIs treatment | [59]       |

CEA, carcinoembryonic antigen; CEC, circulating epithelial cells; cf-DNA, circulating free-DNA; cf-RNA, circulating free-RNA; CTC, circulating tumor cell; ct-DNA, circulating tumor-DNA; DTC, differentiated thyroid cancer; EV, extracellular vesicles; FA, follicular adenoma; FTC, follicular thyroid cancer; mi-RNA, micro-RNA; PTC, papillary thyroid cancer; RAI, radioactive iodine; TC, thyroid cancer; TKI, tyrosine kinase inhibitors; TSHR, thyroid stimulating hormone receptor.

In the pre-operative setting, the expression of genes associated with CTCs can help distinguish benign from malignant thyroid nodules with the follicular feature. For example, the expression of the CTC-associated gene *SLC5A5* is lower in liquid biopsies of patients with FTC compared to patients with follicular adenoma (FA), while *LGALS3* expression is higher in PTC than in FTC patients [34]. In the follow-up of surgically removed PTCs, serum levels of circulating epithelial cells (CECs) expressing epithelial cell adhesion molecule (EpCAM) and thyroid-stimulating hormone receptor (TSHR) are significantly higher in patients with disease recurrence and undetectable serum Tg due to TgAb [35]. Evaluating cf-DNA quantity, integrity, mutational profile, and methylation levels can be useful for the diagnostic definition of DTC [60,61]. Indeed, cf-DNA quantity and integrity appear to be higher in patients with a cytological diagnosis of DTC than in unaffected subjects [36,37]. Conversely, mitochondrial cf-DNA (mcf-DNA) is lower in the same subset of patients [37]. Results of the feasibility and significance of *BRAF-V600E* detection in cf-DNA of DTC patients remain controversial [62–67]. Although this mutation can be
retrieved in cf-DNA from both FTCs and PTCs patients, it is more common in the second histotype [38]. In a retrospective study, measuring the methylation levels of five genes on cf-DNA (calcitonin, E-cadherin, tissue inhibitor of metalloproteinase 3, death-associated protein kinase, and retinoic acid receptor-β2) displayed 77% accuracy in the differential diagnosis between DTCs and benign nodules [39]. In another study, the decrease of 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) levels in cf-DNA predicted the probability of a thyroid cancer diagnosis [40]. More recently, Kathami et al. demonstrated that hypermethylation of MGMT promoter in ct-DNA correlates with the presence of PTC [41]. Interestingly, combining the cf-DNA quantity measurement with the detection of BRAF-V600E, SLCA8, and SLC26A4 hypermethylation can also assist in the early diagnosis of PTC [42].

Circulating free-RNA has also been investigated as a potential diagnostic marker of DTCs. For instance, carcinoembryonic antigen (CEA) messenger RNA (mRNA) can be found in the serum of patients with FTC but not in those with benign lesions [43], while blood measurement of TSHR mRNA can improve the pre-operative detection of DTC when associated with FNAB [44].

The role of circulating mi-RNAs in the diagnosis of PTC has been extensively investigated and recently reviewed. Comprehensively, a set of mi-RNAs (mi-RNA-375, 34a, 145b, 221, 222, 155, Let-7, and 181b) can be designated as a diagnostic biomarker to distinguish PTCs from benign nodules and identify cancer at an early stage [45]. Additional evidence suggests that plasma-derived mi-RNA-222 and another set of circulating mi-RNAs (let-7a, let-7c, let-7d, and let-7i) can be significantly increased in PTC patients compared to subjects with goiter or healthy controls [46,47]. In a prospective observational study, the serum levels of 754 mi-RNAs were measured in 11 PTC patients before and after surgery. Among these, mi-RNA-146 and mi-RNA-221 were further validated as tumor biomarkers during post-surgical follow-up and showed a significant correlation with disease recurrence, even in patients with low Tg levels [48].

Moreover, specific changes in EV mi-RNA profiles appear to correlate with the development of PTC. Indeed, mi-RNA-31-5p is over-expressed in EVs from PTC patients, while mi-RNA-21 and mi-RNA-181a-5p differentiate FTC from PTC [49]. More recently, the overexpression of four mi-RNAs (Let-7b, Let-7d, Let-7f, and Let-7g) in thyreo-peroxidase (TPO)-positive EVs accurately distinguished FTC from FA [50].

2.2. Liquid Biopsy for Prognostic Definition of Differentiated Thyroid Cancer

Liquid biopsy can also be used to predict the clinical course of DTC, by the evaluation of CTCs, cf-DNA, and mi-RNAs (Figure 2a and Table 1).

Using negative enriching immunofluorescence in situ hybridization (NE-iFISH), Qiu et al. showed a potential prognostic implication of CTC count in DTC patients. In their study, the identification of five or more CTCs correlated with the presence of metastasis, while isolating seven or more CTCs predicted poor response to RAI [51]. In another study, the number of CTCs was significantly higher in subjects with a previous DTC compared to healthy controls, and the number of cells isolated was proportional to the tumor stage at diagnosis. Additionally, patients with no evidence of disease recurrence who received RAI >8 years previously had more CTCs compared to those with a shorter treatment-free interval [52].

In a cohort of 57 PTC patients, 24 harbored BRAF-V600E in ct-DNA. The presence of this mutation was associated with disease aggressiveness since it correlated with tumor size, multifoccal growth, extra-thyroidal gross extension, and pulmonary micro-metastasis [53]. Similarly, an increase in the plasma level of mi-RNA-222 and mi-RNA-146 appears to predict poor outcomes in DTC patients [54].
2.3. Liquid Biopsy in the Treatment of Differentiated Thyroid Cancer

Liquid biopsy can also be exploited to monitor response to treatment in patients with DTC. CTC count, ct-DNA, and cf-RNA can potentially outperform serum Tg measurement or radiological imaging as response evaluation methods (Figure 2a and Table 1).

In a pilot study, an early decrease in CEC counts after RAI treatment correlates with disease response in DTC patients [55]. Zheng and colleagues investigated sodium/iodide symporter (NIS) expression in CTCs from DTC patients and found a correlation between a decreased or unchanged number of total NIS+ CTCs and the efficacy of RAI therapy [56].

According to a study by Allin et al., changes in ct-DNA levels can anticipate tumor progression compared to Tg in patients receiving targeted therapies for DTC [57]. Using co-amplification at lower denaturation temperature-PCR (COLD-PCR) in combination with digital droplet polymerase chain reaction (ddPCR), Jensen et al. identified BRAF-V600E mutation cf-DNA in 57 PTC patients. According to their results, BRAF-V600E-mutated patients display nearly five-fold higher odds of achieving an incomplete response to RAI [53]. Measurement of BRAF-V600E mutant ct-DNA can also be informative of the presence of minimal residual disease. In a cohort of BRAF-V600E mutated PTC patients, levels of BRAF-V600E mutant ct-DNA were higher in the case of disease persistence (0–2.07%) compared to no evidence of disease (0–0.04%). Similarly, ct-DNA copy numbers were higher in patients with metastases (20 copies/mL) than in those without residual disease after thyroidectomy (1 copy/mL) [58].

Additionally, the levels of BRAF-V600E cf-RNA appear to decrease after surgery and during systemic treatment with RAI or TKIs in patients with early, recurrent or advanced PTC [59].

3. Liquid Biopsy in Poorly Differentiated and Anaplastic Thyroid Cancer

Poorly differentiated and anaplastic thyroid tumors represent rare and aggressive entities and little is known about the role of liquid biopsy in their management.

In some real-world experiences, cf-DNA has been employed in ATC patients to identify actionable mutations (i.e., BRAF-V600E) [68,69] and to anticipate disease response or progression before they become radiologically apparent [70] (Figure 2b and Table 2).

Table 2. Potential implications of liquid biopsy for the diagnosis, prognostic definition, and therapy of poorly differentiated/anaplastic thyroid cancer.

| Clinical Application | Sample Type | Object | Modification | References |
|----------------------|-------------|--------|--------------|------------|
| Diagnosis            | cf-DNA      | TP53, BRAF and PIK3CA mutations BRAF-V600E detection | Concordance with mutations retrieved in tumor tissue | [71] |
|                      |             |        |              | [72]       |
| Prognosis            | cf-DNA      | PIK3CA mutation BRAF-V600E detection NRAS and TP53 mutations | Worse OS in ATC Increased in ATC progression Higher in progressive PDTC and ATC | [71] |
|                      |             |        |              | [72]       |

ATC, anaplastic thyroid cancer; cf-DNA, circulating free-DNA; OS, overall survival; PDTC, poorly differentiated thyroid cancer; TKI, tyrosine kinase inhibitor.

Recently, Qin et al. examined the concordance of ATC-related mutations in cf-DNA with those detected in tumor tissue, trying to determine the prognostic significance of cf-DNA mutations. As expected, TP53, BRAF, and PIK3CA were the most frequently mutated genes. In 28 treatment-naïve ATC patients, the concordance rate of detected mutations in TP53, BRAF, and PIK3CA between cf-DNA and matched tissue was 82.1%, 92.9%, and 92.9%, respectively. Moreover, patients with a PIK3CA mutation detected on cf-DNA had worse overall survival (OS) [71]. The same group evaluated the employment of ddPCR for the identification of BRAF-V600E mutation on cf-DNA in 44 ATC patients, finding a 93% concordance rate with DNA sequencing on tumor tissue. Additionally,
dynamic measurement of BRAF-V600E levels by ddPCR during treatment was available for 16 patients. Whether the reduction in circulating biomarker levels correlated with tumor shrinkage, their increase was weakly associated with disease progression [72]. However, other research found that an increase in mutations in circulating NRAS and TP53 in a PDTC and an ATC patient anticipated, by several months, radiological disease progression [57].

4. Liquid Biopsy in Medullary Thyroid Cancer

Several studies are accumulating about the use of liquid biopsy in MTC patients to detect and analyze CTCs, cf-DNA, and mi-RNAs (Figure 2c and Table 3).

Table 3. Potential implications of liquid biopsy for the diagnosis, prognostic definition, and therapy of medullary thyroid cancer.

| Clinical Application | Sample Type | Object | Modification | References |
|----------------------|-------------|--------|--------------|------------|
| Diagnosis            | cf-DNA      | cf-DNA amount | Higher in MTC | [42]       |
|                      | mi-RNA      | mi-RNA-222-3p and mi-RNA-17-5p | Higher in MTC | [73]       |
|                      |             | mi-RNA-375 | | [74]       |
|                      |             | mi-RNA-144 and mi-RNA-34a | Higher in active disease | [75]       |
|                      | CTC         | Ctn+ CTC level | Higher in MTC with worse prognosis | [76]       |
|                      |             | CTC detection | Concordance with OS and mortality risk | [77,78]   |
|                      |             | CTC detection | Higher in metastatic cancer | [79]       |
|                      | cf-DNA      | RET-M918T detection RET and BRAF mutations | Correlation with worse OS | [80]       |
|                      |             | mi-RNA-375 | Higher in metastatic cancer and reduced OS | [74]       |
|                      | mi-RNA      | mi-RNA-375 | Higher in metastatic cancer and reduced OS | [74]       |
|                      | cf-DNA      | RET mutations | Correlation with selpercaptinib resistance | [81]       |

Circulating tumor cells showed a prognostic and predictive role in this subset of patients. In a recent report, calcitonin positive (Ctn+) CTCs were identified in the serum of 15 patients with surgically removed MTC, up to 12 years after initial diagnosis. Of note, high CTC levels were found in the serum of three MTC patients with low blood Ctn. According to the authors, this group of patients may have a poorer prognosis; further validation of these results in larger cohorts are needed [76]. Older reports suggest that cytokeratin 20 (CK20) and gastrine-releasing peptide (GRP) expression can also be used to identify MTC-derived CTCs with good sensitivity and specificity [82]. According to other evidence, the detection and enumeration of CTCs with the approved EpCAM-based CellSerch technology can predict OS and mortality risk in patients with advanced MTC [77,78]. The identification of five or more CTCs in patients with metastatic MTC appears to predict shorter survival [79].

The role of cf-DNA as a marker of tumor diagnosis, prognosis and response to treatment has been reported in MTC. For example, Ctn serum levels and the presence of RET mutation inversely correlated with cf-DNA amount in 58 MTC patients. Hence, cf-DNA may serve as a diagnostic marker of MTC when conventional parameters, such as Ctn and RET, are negative [42]. Similarly, the detection of RET-M918T in cf-DNA appear to predict MTC outcomes more accurately than Ctn doubling time, strongly correlating with worse OS [80]. In a study by Allin and al., RET and BRAF mutations were identified in a cohort of 15 MTC, with a detection rate in cf-DNA of 79%, higher than that found in PTC and FTC patients. Mutations were more frequently detected in MTC patients with metastasis, high tumor burden, and progressive disease, thus predicting an unfavorable prognosis [57].
More recently, \textit{RET} mutations were identified in the cf-DNA of MTC patients developing disease progression after an initial response to selpercatinib. In this study, \textit{RET-V804M} mutation, detected in two patients before treatment initiation, decreased during therapy and reappeared together with \textit{RET-G810} mutations at the start of disease progression. As the detection of these mutations has been linked with selpercatinib resistance, ct-DNA monitoring may facilitate the early identification of unresponsive patients who need alternative therapies [81].

Circulating mi-RNAs can be easily obtained from MTC patients, and their levels correlate with clinical-pathological features and disease prognosis [83]. Zhang et al. analyzed the expression of serum mi-RNA in 15 patients with aggressive MTC. Circulating mi-RNA-222-3p and mi-RNA-17-5p were significantly upregulated in MTC patients and discriminated between subjects with MTC and those with benign or healthy nodules [73]. Romeo et al. identified 51 mi-RNAs differentially expressed in a cohort of locally advanced and metastatic MTC patients. Among them, mi-RNA-375 levels were significantly higher in patients with active disease than in those unaffected or cured. Of note, elevated levels of mi-RNA-375 correlated with distant metastasis and reduced OS, but not with disease response to vandetanib [74]. Another study evaluated plasma levels of mi-RNA-144 and mi-RNA-34a in 25 RET-mutant and 25 RET-wild type MTC patients and compared them to healthy controls. According to their results, blood levels of mi-RNA-144 and mi-RNA-34a were higher in cancer patients, especially if RET mutant, than in controls. However, these data were not significantly associated with MTC prognosis [75].

5. Conclusions

In this review, we discussed the potential applications of liquid biopsy in TC. As the incidence of thyroid carcinomas is increasing over time, more effective tools for the management of these tumors are needed. In this context, liquid biopsy is a promising alternative during the diagnostic workup, prognostic definition, therapeutic choices, and follow-up of TC patients.

Liquid biopsy offers many advantages compared to traditional tissue biopsy, such as less invasiveness, few side-effects, repeatability, and representativeness of tumor heterogeneity. Moreover, the applications of liquid biopsy are continually broadening [84], with the development of new techniques such as CellSearch\textsuperscript{®} and DEPArray\textsuperscript{®} for CTC detection and characterization, or automation of ct-DNA isolation [30]. Given the rapid evolution and improvement in this field, other applications may emerge in the future for the management of different TC subtypes. To pursue personalized medicine, \textit{BRAF} mutations in PTC or \textit{RET} alterations in MTC can be routinely screened through liquid biopsy to assess sensitivity towards targeted agents and to monitor the onset of resistance. However, the use of liquid biopsy in TC still poses several challenges, mainly depending on the sensitivity and specificity of the different methods, and tumor subtypes and stages. Additionally, liquid biopsy often displays standardization, reproducibility, and validity issues [85]. Other technical problems may rely on the quantity of circulating material retrieved, especially in the context of early-stage disease and in terms of CTCs and ct-RNA. This latter aspect may represent a major limitation of liquid biopsy in TCs harboring pathogenic rearrangements, such as those involving \textit{RET} or the \textit{neurotrophic receptor tyrosine kinase} (NTRK).

In conclusion, although the clinical utility of liquid biopsy in TC is progressively consolidating over time, efforts are needed to incorporate this technology into clinical practice, as already happens in many other tumor types, e.g., lung cancer [86]. Even though it is unlikely that liquid biopsy will completely substitute tissue biopsy, soon the two techniques may be complementary. In this context, international consortia such as the European Liquid Biopsy Society and the US-based BloodPAC are working to move liquid biopsy from the bench to the bedside.
Author Contributions: Conceptualization, L.M.; data curation, L.M.; writing—original draft preparation, C.R., F.M., M.S.P., S.S., M.M., E.T., S.R.V., S.D.G., A.P. and L.M.; formal analysis, C.T.; writing—review and editing, C.R., F.M., and L.M.; supervision, L.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: Federica Martorana: honoraria from Pfizer, Lilly, and Novartis. The other authors declare no conflict of interest.

References

1. Brown, R.L.; De Souza, J.A.; Cohen, E.E. Thyroid cancer: Burden of illness and management of disease. J. Cancer 2011, 2, 193–199. [CrossRef] [PubMed]
2. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [CrossRef] [PubMed]
3. Olson, E.; Wintheiser, G.; Wolfe, K.M.; Droessler, J.; Silberstein, P.T. Epidemiology of thyroid cancer: A review of the national cancer database, 2000–2013. Cureus 2019, 11, e4127. [CrossRef]
4. Lloyd, R.V. WHO classification of tumours of endocrine organs. IARC 2017, 10, 354.
5. Kure, S.; Ohashi, R. Thyroid hürthle cell carcinoma: Clinical, pathological, and molecular features. Cancers 2020, 13, 26. [CrossRef]
6. Schlumberger, M.; Leboulleux, S. Current practice in patients with differentiated thyroid cancer. Nat. Rev. Endocrinol. 2021, 17, 176–188. [CrossRef]
7. Volante, M.; Lam, A.K.; Papotti, M.; Tallini, G. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: What do pathologists need to know? Endocr. Pathol. 2021, 32, 63–76. [CrossRef]
8. Barletta, J.A.; Nosé, V.; Sadow, P.M. Genomics and epigenomics of medullary thyroid carcinoma: From sporadic disease to familial manifestations. Endocr. Pathol. 2021, 32, 35–43. [CrossRef] [PubMed]
9. Manzella, L.; Stella, S.; Pennisi, M.S.; Tirrò, E.; Massimino, M.; Romano, C.; Puma, A.; Tavarelli, M.; Vigneri, P. New insights in thyroid cancer and p53 family proteins. Int. J. Mol. Sci. 2017, 18, 1325. [CrossRef]
10. Tirrò, E.; Martorana, F.; Romano, C.; Vitale, S.R.; Motta, G.; Di Gregorio, S.; Massimino, M.; Pennisi, M.S.; Stella, S.; Puma, A.; et al. Molecular alterations in thyroid cancer: From bench to clinical practice. Genes 2019, 10, 709. [CrossRef] [PubMed]
11. Massimino, M.; Vigneri, P.; Fallica, M.; Fidilio, A.; Aloisi, A.; Frasca, F.; Manzella, L. IRF5 promotes the proliferation of human thyroid cancer cells. Mol. Cancer 2012, 11, 21. [CrossRef]
12. Messina, R.L.; Sanfilippo, M.; Vella, V.; Pandini, G.; Vigneri, P.; Nicolosi, M.L.; Giani, F.; Vigneri, R.; Frasca, F. Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells. Int. J. Cancer 2011, 130, 2259–2270. [CrossRef]
13. Prete, A.; De Souza, P.B.; Censi, S.; Muzzia, M.; Nucci, N.; Sponziello, M. Update on fundamental mechanisms of thyroid cancer. Front. Endocrinol. 2020, 11, 102. [CrossRef]
14. Ghafouri-Fard, S.; Shirvani-Farsani, Z.; Taheri, M. The role of microRNAs in the pathogenesis of thyroid cancer. Non-Coding RNA Res. 2020, 5, 88–98. [CrossRef] [PubMed]
15. Mazeh, H.; Deutch, T.; Karas, A.; Bogardus, K.A.; Mizrahi, I.; Gur-Wahnon, D.; Ben-Dov, I.Z. Next-generation sequencing identifies a highly accurate miRNA panel that distinguishes well-differentiated thyroid cancer from benign thyroid nodules. Cancer Epidemiol. Biomark. Prev. 2018, 27, 858–863. [CrossRef] [PubMed]
16. Santiago, K.; Wongworawat, Y.C.; Khan, S. Differential MicroRNA-signatures in thyroid cancer subtypes. J. Oncol. 2020, 2020, 2052306. [CrossRef] [PubMed]
17. Cañadas-Garre, M.; Becerra-Massere, P.; Casares, M.L.D.L.T.; Moral, J.V.-D.; Céspedes-Mas, S.; Vilchez-Joyà, R.; Fuentes, T.M.-D.; García-Calvente, C.; Piérola-Maroto, G.; Lopez-Nevo, M.A.; et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAFV600E mutation on fine-needle aspiration biopsy specimens. Ann. Surg. 2012, 255, 986–992. [CrossRef] [PubMed]
18. Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.; Newbold, K.; Papotti, M.; Berruti, A. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 1856–1883. [CrossRef] [PubMed]
19. Massimino, M.; Tirrò, E.; Stella, S.; Frasca, F.; Vella, V.; Sciacca, L.; Pennisi, M.S.; Vitale, S.R.; Puma, A.; Romano, C.; et al. Effect of combined epigenetic treatments and ectopic nis expression on undifferentiated thyroid cancer cells. Anticancer Res. 2018, 38, 6653–6662. [CrossRef] [PubMed]
20. Rao, S.N.; Zafeero, M.; Dadu, R.; Busaidy, N.L.; Hess, K.; Cote, G.J.; Williams, M.D.; William, W.N.; Sandulache, V.; Gross, N.; et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 2017, 27, 672–681. [CrossRef] [PubMed]
21. Manzella, L.; Massimino, M.; Stella, S.; Tirrò, E.; Pennisi, M.S.; Martorana, F.; Motta, G.; Vitale, S.R.; Puma, A.; Romano, C.; et al. Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment. Int. J. Mol. Sci. 2019, 20, 3258. [CrossRef]
22. Krajewska, J.; Gawlik, T.; Jarzab, B. Advances in small molecule therapy for treating metastatic thyroid cancer. Expert Opin. Pharmacother. 2017, 18, 1049–1060. [CrossRef]

23. Porter, A.; Wong, D.J. Perspectives on the treatment of advanced thyroid cancer: Approved therapies, resistance mechanisms, and future directions. Front. Oncol. 2021, 10, 592202. [CrossRef]

24. Priya, S.R.; Dravid, C.S.; Digumarti, R.; Dandekar, M. Targeted therapy for medullary thyroid cancer: A review. Front. Oncol. 2017, 7, 238. [CrossRef] [PubMed]

25. De Rubis, G.; Krishnan, S.R.; Bebawy, M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol. Sci. 2019, 40, 172–186. [CrossRef] [PubMed]

26. Alix-Panabieres, C.; Pantel, K. Liquid biopsy: From discovery to clinical application. Cancer Discov. 2021, 11, 858–873. [CrossRef]

27. Ignatiadis, M.; Lee, M.; Jeffrey, S.S. Circulating tumor cells and circulating tumor DNA: Challenges and opportunities on the path to clinical utility. Clin. Cancer Res. 2015, 21, 4786–4800. [CrossRef] [PubMed]

28. Gold, B.; Cankovic, M.; Furtado, L.V.; Meier, F.; Gocke, C.D. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? J. Mol. Diagn. 2015, 17, 209–224. [CrossRef]

29. Von Bubnoff, N. Liquid biopsy: Approaches to dynamic genotyping in cancer. Oncol. Res. Treat. 2017, 40, 409–416. [CrossRef] [PubMed]

30. Van Dessel, L.F.; Vitale, S.R.; Helmijr, J.C.A.; Wilting, S.M.; Vlugt-Daane, M.; Hoop, E.O.-D.; Sleijfer, S.; Martens, J.W.M.; Jansen, M.P.H.M.; Lokkema, M.P.; et al. High-throughput isolation of circulating tumor DNA: A comparison of automated platforms. Mol. Oncol. 2018, 13, 392–402. [CrossRef]

31. Pös, O.; Bró, O.; Szemes, T.; Nagy, B. Circulating cell-free nucleic acids: Characteristics and applications. Eur. J. Hum. Genet. 2018, 26, 937–945. [CrossRef] [PubMed]

32. Vitale, S.R.; Helmijr, J.A.; Gerritsen, M.; Coban, H.; van Dessel, L.F.; Beije, N.; van der Vlugt-Daane, M.; Vigneri, P.; Sieuwerds, A.M.; Dits, N.; et al. Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer. BMC Cancer 2021, 21, 1–17. [CrossRef] [PubMed]

33. Xu, R.; Rai, A.; Chen, M.; Suwakulsiri, W.; Greening, D.; Simpson, R.J. Extracellular vesicles in cancer—Implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 2018, 15, 617–638. [CrossRef]

34. Jee, H.-G.; Kim, B.-A.; Kim, M.; Yu, H.W.; Choi, J.Y.; Kim, S.-J.; Lee, K.E. Expression of SLC5A5 in circulating tumor cells may distinguish follicular thyroid carcinomas from adenomas: Implications for blood-based preoperative diagnosis. J. Clin. Med. 2019, 8, 257. [CrossRef] [PubMed]

35. Li, Y.-R.; Tseng, C.-P.; Hsu, H.-L.; Lin, H.-C.; Chen, Y.-A.; Chen, S.-T.; Liou, M.-J.; Lin, J.-D. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody. Clin. Chim. Acta 2018, 477, 74–80. [CrossRef] [PubMed]

36. Salvianti, F.; Giuliani, C.; Petrone, L.; Mancini, I.; Vezzosi, V.; Pupilli, C.; Pinzani, P. Integrity and quantity of total cell-free DNA in the diagnosis of thyroid cancer: Correlation with cytological classification. Int. J. Mol. Sci. 2017, 18, 1350. [CrossRef]

37. Perdas, E.; Stawski, R.; Kaczka, K.; Nowak, D.; Zubrzycka, M. Altered levels of circulating nuclear and mitochondrial DNA in 37. Perdas, E.; Stawski, R.; Kaczka, K.; Nowak, D.; Zubrzycka, M. Altered levels of circulating nuclear and mitochondrial DNA in...
46. Kondrotienė, A.; Daukša, A.; Pamedaitytė, D.; Kazokaitė, M.; Žvirblienė, A.; Daukšienė, D.; Šimanavičienė, V.; Klimaitė, R.; Golubickaitė, I.; Stakaitis, R.; et al. Plasma-derived miRNA-222 as a candidate marker for papillary thyroid cancer. Int. J. Mol. Sci. 2020, 21, 6445. [CrossRef]

47. Perdas, E.; Stawski, R.; Kaczka, K.; Zubrzycka, M. Analysis of let-7 family miRNA in plasma as potential predictive biomarkers of diagnosis for papillary thyroid cancer. Diagnostics 2020, 10, 130. [CrossRef] [PubMed]

48. Rosignolo, F.; Zannoni, M.; Giarre, L.; Russo, D.; Fecce, V.; Biffoni, M.; Bellantone, R.; Lombardi, C.P.; Lamartina, L.; Grani, G.; et al. Identification of thyroid-associated serum microRNA profiles and their potential use in thyroid cancer follow-up. J. Endocr. Soc. 2017, 1, 3–13. [CrossRef]

49. Samonosov, R.; Burdakov, V.; Shtam, T.; Radzhabova, Z.; Vasilyev, D.; Titov, S.; Ivanov, M.; Berstein, L.; Filatov, M.; et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumor Biol. 2016, 37, 12011–12021.

50. Zheng, L.; Wang, G.; Guo, W.; Pan, D.; Xie, L.; He, S.; Luo, C.; Li, H.; Ran, Y.; Wu, S.; et al. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioiodine-131 therapy effect in differentiated thyroid cancers. Mol. Biol. Rep. 2019, 46, 4201–4212. [CrossRef]

51. Qiu, Z.-L.; Zhang, H.-J.; Sun, Z.-K.; Chen, X.-T.; Song, H.-J.; Zhang, X.-Y.; Zhang, G.-Q.; Chen, X.-Y.; Luo, Q.-Y. Circulating tumor cells correlate with clinicopathological features and outcomes in differentiated thyroid cancer. Cell. Physiol. Biochem. 2018, 48, 718–730. [CrossRef]

52. Ehlers, M.; Allelein, S.; Schwarz, F.; Hautzel, H.; Kuebart, A.; Schmidt, M.; Haase, M.; Dringenberg, T.; Schott, M. Increased numbers of circulating tumour cells in papillary thyroid cancer patients. Horm. Metab. Res. 2018, 50, 602–608. [CrossRef]

53. Jensen, K.; Thakur, S.; Patel, A.; Mendonca-Torres, M.C.; Costello, J.; Gomes-Lima, C.J.; Walter, M.; Wartofsky, L.; Burman, K.D.; Bikas, A.; et al. Detection of BRAFV600E in liquid biopsy from patients with papillary thyroid cancer is associated with tumor aggressiveness and response to therapy. J. Clin. Med. 2020, 9, 2481. [CrossRef] [PubMed]

54. Gómez-Pérez, A.M.; Pareja, I.M.C.; Alemán, J.G.; Aragüez, L.C.; Ochoa, A.S.; Torres, J.A.; Vega, M.M.; Fernández, C.C.; Doblas, I.M.; Tinahones, F.J. New molecular biomarkers in differentiated thyroid carcinoma: Impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease. Clin. Endocrinol. 2019, 91, 187–194. [CrossRef] [PubMed]

55. Winkens, T.; Pachmann, K.; Freesmeyer, M. The influence of radioiodine therapy on the number of circulating epithelial cells (CEC) in patients with differentiated thyroid cancer—a Pilot study. Exp. Clin. Endocrinol. Diabetes 2014, 122, 246–253. [CrossRef] [PubMed]

56. Zheng, L.; Wang, G.; Guo, W.; Pan, D.; Xie, L.; He, S.; Luo, C.; Li, H.; Ran, Y.; Wu, S.; et al. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioiodine-131 therapy effect in differentiated thyroid cancers. Mol. Biol. Rep. 2019, 46, 4201–4212. [CrossRef]

57. Allin, D.; Shaikh, R.; Carter, P.; Thway, K.; Sharabiani, M.; Gonzales-De-Castro, D.; O’Leary, B.; Garcia-Murillas, I.; Bhide, S.; Hubank, M.; et al. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur. J. Cancer 2018, 103, 165–175. [CrossRef]

58. Almubarak, H.; Qassem, E.; Alghofaili, L.; Alzahrani, A.S.; Karakas, B. Non-invasive molecular detection of minimal residual disease in papillary thyroid cancer patients. Front. Oncol. 2020, 9, 1510. [CrossRef]

59. Lubitz, C.C.; Zhan, T.; Gunda, V.; Amin, S.; Gigiotti, B.J.; Fingeret, A.L.; Holm, T.M.; Wachtel, H.; Sadow, P.M.; Wirth, L.J.; et al. Circulating BRAFV600E Levels correlate with treatment in patients with thyroid carcinoma. Thyroid 2018, 28, 328–339. [CrossRef] [PubMed]

60. Fussey, J.M.; Bryant, J.L.; Batis, N.; Spruce, R.J.; Hartley, A.; Good, J.S.; McCabe, C.J.; Boelaert, K.; Sharma, N.; Mehanna, H. The clinical utility of cell-free DNA measurement in differentiated thyroid cancer: A systematic review. Front. Oncol. 2018, 8, 132. [CrossRef] [PubMed]

61. Wan, J.C.M.; Massie, C.; García-Corbacho, J.; Mouliere, F.; Brenton, J.D.; Caldas, C.; Pacey, S.; Baird, R.; Rosenfeld, N. Liquid biopsy comes of age: Towards implementation of circulating tumour DNA. Nat. Rev. Cancer 2017, 17, 223–238. [CrossRef] [PubMed]

62. Cao, S.; Yu, S.; Yin, Y.; Su, L.; Hong, S.; Gong, Y.; Lv, W.; Li, Y.; Xiao, H. Genetic alterations in cfDNA of benign and malignant thyroid nodules based on amplicon-based next-generation sequencing. Ann. Transl. Med. 2020, 8, 1225. [CrossRef]

63. Chuang, T.C.Y.; Chuang, A.Y.C.; Poeta, L.; Koch, W.M.; Califano, J.A.; Tufano, R.P. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2009, 32, 229–234. [CrossRef]

64. Condello, V.; Macerola, E.; Ugolini, C.; De Napoli, L.; Romei, C.; Materazzi, G.; Elisei, R.; Basolo, F. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head Neck 2018, 40, 1752–1758. [CrossRef]

65. Cradick, K.W.; Milosevic, A.; Rosenberg, A.M.; Erickson, L.A.; Mclver, B.; Grebe, S.K.G. Mutant BRAF799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J. Clin. Endocrinol. Metab. 2009, 94, 5001–5009. [CrossRef]

66. Kim, B.H.; Kim, I.J.; Lee, B.J.; Lee, J.C.; Kim, S.J.; Kim, W.J.; Jeon, Y.K.; Kim, S.S.; Kim, Y.K.; Kim, I.S. Detection of plasma BRAFV600E mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med. J. 2015, 56, 634–640. [CrossRef]
67. Kwak, J.Y.; Jeong, J.J.; Kang, S.-W.; Park, S.; Choi, J.R.; Park, S.-J.; Kim, E.K.; Chung, W.Y. Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas. *Head Neck* 2012, 35, 1630–1633. [CrossRef]  
68. Cabanillas, M.E.; Dadu, R.; Iyer, P.C.; Wanland, K.B.; Busaidy, N.L.; Ying, A.K.; Gule-Monroe, M.; Wang, J.R.; Zafereo, M.; Hofmann, M.-C. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. *Thyroid* 2020, 30, 1288–1296. [CrossRef] [PubMed]  
69. Wang, J.R.; Zafereo, M.E.; Dadu, R.; Ferrarotto, R.; Busaidy, N.L.; Lu, C.; Ahmed, S.; Gule-Monroe, M.K.; Williams, M.D.; Sturgis, E.M.; et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. *Thyroid* 2019, 29, 1036–1043. [CrossRef] [PubMed]  
70. Iyer, P.C.; Dadu, R.; Ferrarotto, R.; Busaidy, N.L.; Habra, M.A.; Zafereo, M.; Gross, N.; Hess, K.R.; Gule-Monroe, M.; Williams, M.D.; et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. *Thyroid* 2018, 28, 79–87. [CrossRef]  
71. Qin, Y.; Wang, J.R.; Yang, J.; Iyer, P.C.; Cote, G.J.; Busaidy, N.L.; Dadu, R.; Zafereo, M.; Williams, M.D.; Ferrarotto, R.; et al. Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma. *Thyroid* 2021. [CrossRef]  
72. Iyer, P.C.; Cote, G.J.; Hai, T.; Gule-Monroe, M.; Bui-Griffith, J.; Williams, M.D.; Hess, K.; Hofmann, M.-C.; Dadu, R.; Zafereo, M.; et al. Circulating BRAF V600E cell-free DNA as a biomarker in the management of anaplastic thyroid carcinoma. *JCO Precis. Oncol.* 2018, 2. [CrossRef]  
73. Zhang, A.; Wang, C.; Lu, H.; Chen, X.; Ba, Y.; Zhang, C.; Zhang, C.-Y. Altered serum MicroRNA profile may serve as an auxiliary tool for discriminating aggressive thyroid carcinoma from nonaggressive thyroid cancer and benign thyroid nodules. *Dis. Markers* 2019, 2019, 3717683. [CrossRef]  
74. Romeo, P.; Colombo, G.; Granata, R.; Calaresu, G.; Gualeni, A.V.; Dugo, M.; de Cecco, L.; Rizzetti, M.G.; Zanframundo, A.; Aiello, A.; et al. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. *Endocr. Relat. Cancer* 2018, 25, 217–231. [CrossRef] [PubMed]  
75. Shabani, N.; Sheikholeslami, S.; Paryan, M.; Yeganeh, M.Z.; Tavangar, S.M.; Azizi, F.; Mohammadi-Yeganeh, S.; Hedayati, M. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. *J. Cell. Physiol.* 2020, 235, 1366–1373. [CrossRef] [PubMed]  
76. Sriramareddy, S.N.; Hamoir, E.; Chavez, M.; Louis, R.; Beckers, A.; Willems, L. Tumor cells may circulate in medullary thyroid carcinoma patients. *Dis. Markers* 2018, 2019, 3717683. [CrossRef]  
77. Baeuerle, P.A.; Gires, O. EpCAM (CD326) finding its role in cancer. *Br. J. Cancer* 2007, 96, 417–423. [CrossRef] [PubMed]  
78. Rao, C.G.; Chianese, D.; Doyle, G.V.; Miller, M.C.; Russell, T.; Sanders, R.A., Jr.; Terstappen, L.W. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. *Int. J. Oncol.* 2005, 27, 49–57. [CrossRef] [PubMed]  
79. Xu, J.Y.; Handy, B.; Michaelis, C.L.; Waguespack, S.G.; Hu, M.I.; Busaidy, N.; Jimenez, C.; Cabanillas, M.E.; Fritsche, H.A.; Cote, G.J.; et al. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. *J. Clin. Endocrinol. Metab.* 2016, 101, 4461–4467. [CrossRef] [PubMed]  
80. Cote, G.J.; Evers, C.; Hu, M.I.; Grubbs, E.G.; Williams, M.D.; Hai, T.; Duose, D.Y.; Houston, M.R.; Bui, J.H.; Mehrotra, M.; et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid cancer. *J. Clin. Endocrinol. Metab.* 2017, 102, 3591–3599. [CrossRef] [PubMed]  
81. Solomon, B.J.; Tan, L.; Lin, J.J.; Wong, S.Q.; Holllizeck, S.; Ebata, K.; Tuch, B.B.; Yoda, S.; Gainor, J.F.; Sequist, L.V.; et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. *J. Thorac. Oncol.* 2020, 15, 541–549. [CrossRef] [PubMed]  
82. Weber, T.; Lacroix, J.; Wörner, S.; Weckauf, H.; Frank-Raue, K.; Eber, M.; Doeberitz, M.V. Detection of hematogenic and lymphogenic tumor cell dissemination in patients with medullary thyroid carcinoma by cytokeratin 20 and preprogastrin-releasing peptide RT-PCR. *Int. J. Cancer* 2003, 103, 126–131. [CrossRef]  
83. Chiacchiarini, M.; Trochianesi, S.; Besharat, Z.M.; Po, A.; Ferretti, E. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer. *Pharmacol. Ther.* 2021, 219, 107708. [CrossRef] [PubMed]  
84. Kilgour, E.; Rothwell, D.; Brady, G.; Dive, C. Liquid biopsy-based biomarkers of treatment response and resistance. *Cancer Cell* 2020, 37, 485–495. [CrossRef] [PubMed]  
85. Geserickx, E.; Hendrix, A. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. *Mol. Asp. Med.* 2020, 72, 100828. [CrossRef] [PubMed]  
86. Rolfo, C.; Mack, P.C.; Scaglioni, G.V.; Baas, P.; Barlesi, F.; Bivona, T.G.; Herbst, R.S.; Mok, T.; Peled, N.; Pirker, R.; et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. *J. Thorac. Oncol.* 2018, 13, 1248–1268. [CrossRef] [PubMed]